NRI Nuvo Reserch Q1 2012 Result

Yet this company had dreamed all the elements before it in order to advance its growth. However with the disappointing result of anonce and with a product that has been Temporarily rejected by the FDA, I believe that shareholders have been had by management. society increased revenues from 3.8 to 6.2 million. That it will be expected as sales of Pensaid increased. The problem with that is operating expenses. $ 2 million for expenses of sales for a company with a turnover of about 15 million per year -20,000,000. Without counting the bonuses and high salaries of dirigeants.I think this company is a joke for shareholders.

Nri.to Nuvo Research inc. Result Prediction Q1

Covidien to results released its quarterly and semi-annual new this week and can already see what was going to be the results of Nuvo Research Inc.. to be released next week. We can see that on the report of Covidien, sales of pharmaceutical product which is found in the poduit Pensaid increased 34% in the quarter from 106 to 142 million. If we anayse the latest results of research Nvo inc. the last quarter 2011 product sales vefrait be around 12 million. We also pourrion see an increase in royalties that could amount to around 7 million. We would therefore increase net profit of 4 million. If everything remains equal for somewhere else, the company should have a slight loss even if the result of sales of pensaid. Research and development and overhead costs are the black beast of this company. Salaries, bonuses and benefits are much too high for this company. In short, we'll see Wednesday what the numbers say that company.

Nri.to Nuvo Research Result Q1 2012

Nuvo Research inc. on TSX market will show they Q1 2012 Thursday 3 may 2012.